PATRICIA: A phase II study of palbociclib and trastuzumab with or without letrozole in previously treated, postmenopausal patients with HER2-positive metastatic breast cancer.

被引：1
|
作者：
Villagrasa, Patricia
Gonzalez, Xavier
Oliveira, Mafalda
Vazquez, Josep
De La Pena, Lorena
Llobet-Canela, Marta
Prat, Aleix
Ciruelos, Eva
机构：
[1] SOLTI Breast Canc Res Grp, Barcelona, Spain
[2] Quiron Dexeus Univ Hosp, Translat Res Unit, Dr Rosell Oncol Inst, Barcelona, Spain
[3] Vall dHebron Univ Hosp VHIO, Barcelona, Spain
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] Hosp Univ 12 Octubre, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps642
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS642
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR plus with or without letrozole) in trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer.
    Villagrasa, Patricia
    Prat, Aleix
    Oliveira, Mafalda
    De La Pena, Lorena
    Gonzalez, Xavier
    Cortes, Javier
    Simon, Sonia Pernas
    Rios, Jose
    Canes, Jordi
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (with or without letrozole in ER plus ) in previously trastuzumab-pretreated, postmenopausal patients with HER2-positive metastatic breast cancer
    Villagrasa Gonzalez, P.
    Prat, A.
    Oliveira, M.
    de la Pena, L.
    Gonzalez, X.
    Cortes Castan, J.
    Rios, J.
    Vazquez, J.
    Martinez Janez, N.
    Perello Martorell, A.
    Garau, I.
    Martinez de Duenas, E.
    Morales, S.
    Mele, M.
    Bermejo De las Heras, B.
    Ciruelos, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] SOLTI-1303 PATRICIA phase II trial (STAGE 1) - Palbociclib and trastuzumab in postmenopausal patients with HER2-positive metastatic breast cancer
    Ciruelos, E.
    Villagrasa, P.
    Pare, L.
    Oliveira, M.
    Pernas, S.
    Cortes, J.
    Soberino, J.
    Adamo, B.
    Vazquez, S.
    Martinez, N.
    Perello, A.
    Bermejo, B.
    Martinez, E.
    Garau, I.
    Mele, M.
    Morales, S.
    Galvan, P.
    Pascual, T.
    Canes, J.
    Nuciforo, P.
    Gonzalez, X.
    Prat, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [4] Phase II study of trastuzumab with irinotecan in HER2-positive gastric cancer previously treated with trastuzumab
    Hatanaka, Kazuteru
    Kawamoto, Yasuyuki
    Yuki, Satoshi
    Meguro, Takashi
    Uebayashi, Minoru
    Abe, Masakazu
    Nakamura, Michio
    Okuda, Hiroyuki
    Sakata, Yuh
    Komatsu, Yoshito
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab
    Kawamoto, Y.
    Yuki, S.
    Meguro, T.
    Hatanaka, K.
    Uebayashi, M.
    Iwanaga, I.
    Nakamura, M.
    Eto, K.
    Okuda, H.
    Abe, M.
    Aonuma, A.
    Abe, N.
    Sato, A.
    Nakatsumi, H.
    Muranaka, T.
    Yagisawa, M.
    Oba, K.
    Sakata, Y.
    Sakamoto, N.
    Komatsu, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab
    Takahide, Sasaki
    Yasuyuki, Kawamoto
    Satoshi, Yuki
    Takashi, Meguro
    Kazuteru, Hatanaka
    Minoru, Uebayashi
    Ichiro, Iwanaga
    Michio, Nakamura
    Kazunori, Eto
    Hiroyuki, Okuda
    Masakazu, Abe
    Ayane, Oba
    Nobuhiko, Abe
    Atsushi, Sato
    Hiroshi, Nakatsumi
    Kazuaki, Harada
    Tetsuhito, Muranaka
    Masataka, Yagisawa
    Koji, Oba
    Yuh, Sakata
    Yoshito, Komatsu
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.
    Cascetta, Krystal Pauline
    Poulikakos, Poulikos
    Shapiro, Charles L.
    Bhardwaj, Aarti Sonia
    Fasano, Julie
    Irie, Hanna
    Klein, Paula
    Goel, Anupama
    Kalinsky, Kevin
    Adams, Sylvia
    Andreopoulou, Eleni
    Jaffer, Shabnam
    Ru, Meng
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer
    Tolaney, S. M.
    Najita, J.
    Sperinde, J.
    Huang, W.
    Chen, W. Y.
    Savoie, J.
    Fornier, M.
    Winer, E. P.
    Bunnell, C.
    Krop, I. E.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1841 - 1847
  • [9] A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer
    Lucas Bayo-Calero, Juan
    Mayordomo, Jose I.
    Salnchez-Rovira, Pedro
    Perez-Carrion, Ramon
    Illaramendi, Jose J.
    Garcia-bueno, Jose M.
    Gonzalez-Flores, Encarnacion
    Crespo, Carmen
    Ramos-Vazquez, Manuel
    Garcia-Palomo, Andres
    Ruiz-Borrego, Manuel
    de la Haba, Juan
    Gomez-Bernal, Amalia
    Yubero-Esteban, Alfonso
    CLINICAL BREAST CANCER, 2008, 8 (03) : 264 - 268
  • [10] A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer.
    Wong, ZW
    Isaacs, C
    Harris, L
    Ellis, MJ
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S106 - S107
12345